Takeaway

• Updated findings from the SOLOIST and SCORED trials indicate significant and early benefits from the sodium-dependent glucose cotransporter 1/2 (SGLT1/2) inhibitor, sotagliflozin in reducing the risk of heart failure (HF) hospitalizations or urgent visits, myocardial infarction (MI), and stroke.

Key points

• SOLOIST-WHF was a multicenter, double-blind trial including 1222...